10-K: Aclarion Inc. Reports 2024 10-K Filing: Focus on Commercialization and Strategic Partnerships

Sentiment:

Annual Report 9 April 2025 1:45 AM

Aclarion's 2024 10-K filing highlights its ongoing efforts to commercialize its NOCISCAN technology, secure payer contracts, and expand strategic relationships within the low back pain market.

Capital raiseThe company may need substantial additional funding to support its continuing operations and pursue its growth strategy.To finance its operations, the company expects to rely on the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions.

Worse than expectedThe company's net loss increased from $4,911,374 in 2023 to $6,992,927 in 2024.

Summary

Aclarion Inc.'s 10-K filing reports financial results for the year ended December 31, 2024, detailing the company's activities in the healthcare technology sector, particularly in addressing the low back and neck pain market.
The company's core technology, MR Spectroscopy, is used in its NOCISCAN product to assist surgeons in determining optimal surgical procedures for patients with lumbar spine pain.
Aclarion is focusing on securing payer contracts to cover Category III CPT codes to drive adoption of its technology among spine surgeons and imaging centers.
The company is prioritizing key markets such as NYC, San Francisco, Chicago, Phoenix, Miami, Denver, Detroit, and Indianapolis, and plans to expand its provider network in these areas.
Aclarion is collaborating with ATEC Spine, Inc. to identify Key Opinion Leader (KOL) surgeons to evaluate NOCISCAN technology and co-market NOCISCAN in targeted markets.
The company is also participating in NIH-funded studies to evaluate data inputs for predicting optimal treatment paths for back pain patients.
Aclarion reported a net loss of $6,992,927 for 2024, compared to a net loss of $4,911,374 in 2023.
As of December 31, 2024, the company had cash of approximately $0.46 million, but subsequent capital raises are expected to fund operations into the third quarter of 2026.
The company acknowledges a material weakness in its internal control over financial reporting and is taking steps to address it.
Aclarion is subject to ongoing FDA regulatory requirements and must comply with healthcare laws and regulations, including those related to data privacy and security.
The company faces competition from existing diagnostic standards like X-ray, lumbar MRI, and provocation discography, as well as potential new technologies.
Aclarion's intellectual property portfolio includes 24 issued patents and 6 pending patent applications in the U.S., and 17 patent grants and 7 pending patent applications outside the United States.
The company is also subject to the General Data Protection Regulation (GDPR) and the California Consumer Privacy Act (CCPA), which impose stringent data protection requirements.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments in terms of strategic partnerships and technology commercialization, the company's financial losses and need for additional funding raise concerns.

Positives

Aclarion is focused on commercializing its NOCISCAN technology for improving surgical outcomes in discogenic low back pain patients.
The company is transitioning to full commercial operations with the introduction of Category III CPT codes and proceeds from its IPO.
Aclarion is collaborating with ATEC Spine, Inc. to evaluate NOCISCAN technology and co-market it in targeted markets.
The company is participating in NIH-funded studies to evaluate data inputs for predicting optimal treatment paths for back pain patients.
Aclarion's intellectual property portfolio includes 24 issued patents and 6 pending patent applications in the U.S., and 17 patent grants and 7 pending patent applications outside the United States.

Negatives

Aclarion reported a net loss of $6,992,927 for 2024, compared to a net loss of $4,911,374 in 2023.
As of December 31, 2024, the company had cash of approximately $0.46 million, but subsequent capital raises are expected to fund operations into the third quarter of 2026.
The company acknowledges a material weakness in its internal control over financial reporting and is taking steps to address it.

Risks

Aclarion may not be able to maintain compliance with the continued listing requirements of the Nasdaq Capital Market.
The company's commercial success depends on attaining significant market acceptance of its technology.
Aclarion's commercial software products currently depend on compatible use with a limited number of MR scanners.
The company may be unable to compete successfully with other available alternatives for diagnosing low back pain.
If adequate reimbursement becomes unavailable for the procedures that use its diagnostic technology, it could diminish sales.
Aclarion's collection, use, storage, disclosure, transfer and other processing of sensitive and personal information could give rise to significant costs and liabilities.
The company's current product is supported by a single clinical study at a single clinical center involving one spine surgeon who has a financial interest in the Company.
To reach the full market potential of its product, Aclarion will need to leverage advanced machine learning and artificial intelligence technologies (AI) to a larger degree than it does today.
The company's current product is dependent on certain processes that are not optimized to support the scaling of its technology.

Future Outlook

Aclarion plans to secure payer contracts, expand its provider network, and continue clinical studies to support the adoption and reimbursement of its NOCISCAN technology. The company also aims to expand its technology to address neck pain populations and explore other clinical applications.

Industry Context

Aclarion operates in the competitive diagnostic and connected care markets, addressing the $134.5B U.S. low back and neck pain market. The company's technology aims to improve upon existing diagnostic standards like lumbar MRI and provocation discography.

Comparison to Industry Standards

The document states that surgical success rates for LBP range from 41 to 57%, with 5-16% early complication and reoperation rates.
The document references a clinical study in the European Spine Journal in April 2019, showing that 97% of patients met the criteria for clinical improvement when all discs identified as painful by NOCISCAN were included in the surgical treatment, compared to only 54% when discs identified as painful were not included.
The document references a peer-reviewed journal article detailing the Gornet 2-year outcomes published in the European Spine Journal in April 2023, showing that 85% of patients improved when disc(s) identified as consistent with pain by our technology were included in a surgical treatment, compared to only 63% of patients when disc(s) identified as consistent with pain were not treated or disc(s) identified as consistent without pain were treated.

Stakeholder Impact

Shareholders may experience dilution from future equity offerings.
Employees may be affected by the company's ability to secure funding and execute its business plan.
Customers (surgeons and imaging centers) may benefit from improved diagnostic tools and treatment options.
Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

Secure payer contracts to cover Category III CPT codes.
Expand the provider network to include additional imaging centers and surgeons.
Enhance the multi-tiered sales/marketing/branding campaign.
Continue to conduct clinical trials and publish results.
Pursue additional applications of the technology.

Key Dates

Date	Description
2005	Early research published by Aclarion co-Founder Jeffrey Lotz, PhD, at UCSF.
2008-01-08	Company entered into an Exclusive License Agreement with the Regents of the University of California.
2011	Collaborative relationship with Siemens began.
2012-05-02	Memorandum of Understanding (MOU) with SIEMENS.
2014-12-09	Amended and restated exclusive license agreement with the Regents of the University of California.
2015	NuVasive, Inc. purchased approximately $2.0 million of the Company's Series B preferred shares.
2016-12-13	21st Century Cures Act signed into law.
2017-03-31	Further amendment to the License Agreement with the Regents of the University of California.
2017-12-31	Strategic Collaboration Agreement for Phased Commercialization of the SIEMENS-compatible NOCISCAN Product of Aclarion, Inc. entered into with SIEMENS Healthcare GmbH.
2018-05-25	General Data Protection Regulation (GDPR) implemented in the EU.
2019-04	Clinical study published in the European Spine Journal.
2020-02	NuVasive agreed to purchase $308,720 of convertible notes.
2020-01-01	California Consumer Privacy Act (CCPA) became effective.
2021-01-01	Category III CPT codes became effective.
2021-05	Certain aspects of the new MDR placed new requirements on Class I medical devices.
2021-05-26	Medical Devices Regulation (MDR) went into effect.
2021-09-15	Brent Ness became Chief Executive Officer.
2021-12-03	Company changed its name to Aclarion, Inc.
2022-04-21	Aclarion IPO.
2023-04	Aclarion advanced the evidence of our technology with a peer-reviewed journal article detailing the Gornet 2-year outcomes published in the European Spine Journal.
2024-01-08	Executed a strategic partnership agreement with ATEC Spine, Inc.
2024-01-03	Company effected a 1:16 reverse stock split of the Company's common stock.
2024-02-27	Company completed a public offering of 5,175,000 units.
2024-08-14	Company entered into an exchange agreement with the Series B Notes Payable holders to exchange $ 930,052 of principal and accrued interest on the notes for 930 shares of newly issued Series B convertible preferred stock.
2024-09-30	Company entered into a securities purchase agreement with accredited investors for a convertible preferred stock and warrants financing.
2025-01-01	Company had an automatic increase of 619,499 shares to the 2022 Equity Incentive Plan.
2025-01-03	Company gave notice to terminate the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC.
2025-01-15	Company sold, in an underwritten public offering, an aggregate of (i) 100,000 shares of the Company's common stock, (ii) 143,900,000 pre-funded warrants, (iii) 144,000,000 Series A Common Warrants, and (iv) 144,000,000 Series B Common Warrants.
2025-01-22	Company redeemed all Series B Preferred Stock and related accrued dividends with a cash payment of $1,213,590.
2025-01-29	Company effected a reverse stock split at a ratio of 1:335.
2025-03-05	Company convened its Special Meeting of Stockholders. Stockholders approved the full issuance of shares of common stock issuable by the Company upon exercise of the Series A Common Warrants and the Series B Common Warrants.
2025-03-27	Company effected a reverse stock split at a ratio of 1:27.

Keywords

NOCISCAN, low back pain, MR Spectroscopy, CPT codes, payer contracts, strategic partnerships, clinical studies, market commercialization, intellectual property, financial results, Aclarion

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.